NCT01848002已完成1 期
A Randomized, Placebo-Controlled, Double-Blind, Multi-dose Study of the Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 24
- 主要终点
- Incidence of adverse events
研究概览
简要总结
This trial was conducted in Europe. The aim of this trial was to investigate safety and pharmacokinetics of multiple doses of catridecacog (recombinant factor XIII, rFXIII) in healthy volunteers.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 65 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Normal platelet count and clotting parameters
- •Adequate renal and hepatic function
- •Negative serum pregnancy test within 21 days prior to enrollment and negative urine pregnancy test on admission to the clinical research unit (if subject female and of child-bearing potential)
- •Agreement to use a medically accepted form of contraception from the time of enrollment to completion of all follow-up study visits (if subject a sexually active male or female of childbearing potential)
- •Negative drug and negative alcohol screens
排除标准
- •Known antibodies or hypersensitivity to FXIII
- •Known bleeding or hematologic disorder
- •Known allergy to yeast
- •Receipt of blood products within 30 days of screening
- •Donation of blood within 30 days prior to enrollment
- •Surgical procedure of any type within 30 days prior to enrollment
- •History of autoimmune disorders involving autoantibodies, e.g., systemic lupus erythematosus
- •Treatment with any experimental agent within 30 days of study enrollment
研究组 & 干预措施
rFXIII
Experimental
干预措施: catridecacog (Drug)
Placebo
Placebo Comparator
干预措施: placebo (Drug)
结局指标
主要结局
Incidence of adverse events
时间窗: Days 0-33
次要结局
- Incidence of clinically significant changes from baseline in physical examination or laboratory measurements(From days -1 through day 33)
- Incidence of rFXIII antibodies, as measured by ELISA (Enzyme-Linked Immuno Sorbent Assay)(From days -1 through day 33)
- Incidence of yeast antibodies(From days -1 through day 33)
研究者
相似试验
已完成
2 期
A Multiple Dose Trial of NNC 0151-0000-0000 in Subjects With Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT01223911Novo Nordisk A/S34
已完成
1 期
Safety and Tolerability of Anti-IL-20 in Subjects With Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT01038674Novo Nordisk A/S16
已完成
1 期
First-in-man Trial of NNC0142-0002 in Patients With Rheumatoid ArthritisInflammationRheumatoid ArthritisNCT00927927Janssen Research & Development, LLC65
已完成
1 期
Safety, Tolerability, and Profile of Action of Drug in the Body of NN9535 in Healthy Male Japanese and Caucasian SubjectsHealthyDiabetesNCT00851773Novo Nordisk A/S84
已完成
1 期
Dose Escalation Trial of Single Subcutaneous Doses of NNC 0113-0217 to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics in Healthy Male SubjectsHealthyDiabetesDiabetes Mellitus, Type 2NCT03144271Novo Nordisk A/S58